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In the present study, we investigated the in-vitro anti-cancer potential of six diarylpentanoids 
against a panel of BRAF- and KRAS-mutated colorectal cancer cell lines including T84, SW620, 
LoVo, HT29, NCI-H508, RKO, and LS411N cells. Structure-activity relationship study suggested 
that the insertions of tetrahydro-4H-thiopyran-4-one and brominated phenyl moieties are essential 
for better cytotoxicity. Among the evaluated analogs, 2e has been identified as the lead compound 
due to its low IC50 values of approximately 1 µM across all cancer cell lines and high 
chemotherapeutic index of 7.1. Anti-proliferative studies on LoVo cells showed that 2e could 
inhibit cell proliferation and colony formations by inducing G2/M cell cycle arrest. Subsequent 
cell apoptosis assay confirmed that 2e is a Bcl-2 inhibitor that could induce intrinsic cell apoptosis 
by creating a cellular redox imbalance through its direct inhibition on the Bcl-2 protein. Further 
molecular docking studies revealed that the bromophenyl moieties of 2e could interact with the 
Bcl-2 surface pocket through hydrophobic interaction, while the tetrahydro-4H-thiopyran-4-one 
fragment could form additional Pi-sulfur and Pi-alkyl interactions in the same binding site. In all, 
the present results suggest that 2e could be a potent lead that deserves further modification and 
investigation in the development of a new Bcl-2 inhibitor. 
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